

Sarah Anderson

July 10, 2026

 **DRAFT**

Stage IV High-Grade Serous Ovarian Cancer

CANCER TYPE

Ovarian Cancer

STAGE

Stage IV

KEY MUTATIONS

4 found

TREATMENT OPTIONS

3 identified

What This Means

You have Stage IV High-Grade Serous Ovarian Carcinoma, an advanced form of ovarian cancer that has spread beyond the ovaries. Your tumor carries important genetic markers — including a BRCA1 germline mutation, HRD-positivity, a strong neoantigen vaccine target, and an actionable PIK3CA mutation — that open the door to several targeted therapies and clinical trial opportunities.

Key Findings

 **BRCA1:** You carry an inherited BRCA1 change. PARP inhibitor drugs exploit this defect to kill cancer...

 **TP53:** Creates neoantigen peptide RMPEAAPPV — confirmed strong HLA-A*02:01 binder at IC50=7.8 nM.

 **PIK3CA:** Activates the PI3K cell-growth pathway. Blockable with alpelisib.

 **CCNE1:** CCNE1 amplification signals platinum resistance but creates a Wee1 dependency that can be targeted.

Recommended Treatments

Treatment	Type	Evidence
Olaparib (Lynparza) or Niraparib (Zejula)	targeted	FDA Approved
Neoantigen Peptide Vaccine (RMPEAAPPV)	immunotherapy	Clinical Trial Only
Alpelisib + Adavosertib combination	targeted	Clinical Trial Only

Next Steps

1. Discuss this report with your oncologist
2. Review treatment options together
3. Ask about 1 clinical trial(s) you may qualify for
4. Schedule genetic counseling for family discussion
5. Follow your monitoring schedule

Questions?

Your oncology nurse navigator
or on-call oncologist

Important

AI-generated summary. Must be reviewed
by your healthcare team.